Dinić M, Tasić G, Stanković-Dordević D, Otašević L, Tasić M, Karanikolic A. Serum anti-Helicobacter pylori IgA and IgG antibodies in asymptomatic children in Serbia. Scandinavian Journal of Infectious Diseases. 2007;39(4):303–7.
2.
Molinari M, Salio M, Galli C, Norais N, Rappuoli R, Lanzavecchia A, et al. Selective Inhibition of Ii-dependent Antigen Presentation by Helicobacter pylori Toxin VacA. The Journal of Experimental Medicine. 1998;187(1):135–40.
3.
Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA , cagA , and vacA Status and Clinical Outcome: Studies in Four Different Countries. Journal of Clinical Microbiology. 1999;37(7):2274–9.
4.
Smoot DT, Mobley HL, Chippendale GR, Lewison JF, Resau JH. Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infection and Immunity. 1990;58(6):1992–4.
5.
Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proceedings of the National Academy of Sciences. 1999;96(22):12778–83.
6.
Yamaoka Y, Souchek J, Odenbreit S, Haas R, Arnqvist A, Borén T, et al. Discrimination between Cases of Duodenal Ulcer and Gastritis on the Basis of Putative Virulence Factors of Helicobacter pylori. Journal of Clinical Microbiology. 2002;40(6):2244–6.
7.
Yamaoka Y. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut. 2006;55(6):775–81.
8.
Robinson K, Argent RH, Atherton JC. The inflammatory and immune response to Helicobacter pylori infection. Best Practice & Research Clinical Gastroenterology. 2007;21(2):237–59.
9.
Kosunen TU, Seppäla K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. The Lancet. 1992;339(8798):893–5.
10.
Atherton JC, Cao P, Peek RM, Tummuru MKR, Blaser MJ, Cover TL. Mosaicism in Vacuolating Cytotoxin Alleles of Helicobacter pylori. Journal of Biological Chemistry. 1995;270(30):17771–7.
11.
Ibraghimov A, Pappo J. The immune response against Helicobacter pylori – a direct linkage to the development of gastroduodenal disease. Microbes and Infection. 2000;2(9):1073–7.
12.
Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Letters. 2011;305(2):228–38.
13.
Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. Journal of Clinical Investigation. 2004;113(3):321–33.
14.
Kuipers EJ. Relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Alimentary Pharmacology & Therapeutics. 1998;12(s1):25–36.
15.
Cancer IA. IARC monographs on the evaluation of carcinogenic risks to humans. In: schistosomes, liver flukes and Helicobacter pylori International Agency for Research on Cancer. 1994.
16.
Otasevic M, Nagorni A, Stankovic-Djordjevic D, Dinic M, Otasevic L. Helicobacter pylori and gastric cancer. Archive of Oncology. 2003;11(4):233–7.
17.
Lai LH, Sung JJY. Helicobacter pylori and benign upper digestive disease. Best Practice & Research Clinical Gastroenterology. 2007;21(2):261–79.
18.
Odenbreit S, Püls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of Helicobacter pylori CagA into Gastric Epithelial Cells by Type IV Secretion. Science. 2000;287(5457):1497–500.
19.
Marshall B, Warren JR. UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATION. The Lancet. 1984;323(8390):1311–5.
20.
GOODWIN CS, ARMSTRONG JA, CHILVERS T, PETERS M, COLLINS MD, SLY L, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., Respectively. International Journal of Systematic Bacteriology. 1989;39(4):397–405.
21.
Morris AJ, Ali MR, Nicholson GI, Perez-Perez GI, Blaser MJ. Long-Term Follow-up of Voluntary Ingestion of Helicobacter pylori. Annals of Internal Medicine. 1991;114(8):662–3.
22.
Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Gastroenterology. 1991;100(6):1495–501.
23.
Sobala GM, Crabtree JE, Dixon MF, Schorah CJ, Taylor JD, Rathbone BJ, et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut. 1991;32(11):1415–8.
24.
Ernst PB, Gold BD. The Disease Spectrum ofHelicobacter Pylori: The Immunopathogenesis of Gastroduodenal Ulcer and Gastric Cancer. Annual Review of Microbiology. 2000;54(1):615–40.
25.
Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Alimentary Pharmacology & Therapeutics. 1999;13(s1):3–11.
26.
Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag , a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proceedings of the National Academy of Sciences. 1996;93(25):14648–53.
27.
Bizzozero G. Ueber die schlauchförmigen Drüsen des Magendarmkanals und die Beziehungen ihres Epithels zu dem Oberflächenepithel der Schleimhaut Dritte Mittheilung. Archiv für Mikroskopische Anatomie. 1893;42(1):82–152.
28.
Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nature Reviews Microbiology. 2004;2(9):747–65.
29.
Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nature Immunology. 2004;5(11):1166–74.
30.
Kuipers EJ, Perez-Perez GI, Meuwissen SGM, Blaser MJ. Helicobacter pylori and Atrophic Gastritis: Importance of the cagA Status. JNCI Journal of the National Cancer Institute. 1995;87(23):1777–80.
31.
Blaser MJ, Crabtree JE. CagAand the Outcome ofHelicobacter pyloriInfection. American Journal of Clinical Pathology. 1996;106(5):565–7.
32.
Atherton J, Peek R, Tham K, Cover T, Blaser M. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 1997;112(1):92–9.
33.
Montecucco C, de Bernard M. Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori. Microbes and Infection. 2003;5(8):715–21.
34.
Zhang QB, Etolhi G, Dawodu JB, Husain A, Gemmell CG, Russell RI. Relationship between mucosal levels of interleukin 8 and toxinogenicity of Helicobacter pylori. Inflammopharmacology. 1998;6(2):109–17.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
